4,512 Shares in Lantheus Holdings, Inc. $LNTH Acquired by CSM Advisors LLC

CSM Advisors LLC bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,512 shares of the medical equipment provider’s stock, valued at approximately $370,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LNTH. Signaturefd LLC grew its holdings in shares of Lantheus by 36.5% during the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 116 shares during the period. Quarry LP lifted its position in Lantheus by 2,350.0% in the first quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock valued at $48,000 after buying an additional 470 shares during the last quarter. Parkside Financial Bank & Trust boosted its stake in Lantheus by 20.2% during the second quarter. Parkside Financial Bank & Trust now owns 1,264 shares of the medical equipment provider’s stock worth $103,000 after buying an additional 212 shares during the period. AlphaQuest LLC boosted its stake in Lantheus by 252.5% during the first quarter. AlphaQuest LLC now owns 1,653 shares of the medical equipment provider’s stock worth $161,000 after buying an additional 1,184 shares during the period. Finally, Bayforest Capital Ltd acquired a new stake in shares of Lantheus during the first quarter valued at about $180,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on LNTH. TD Cowen decreased their price objective on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, September 15th. Truist Financial restated a “hold” rating and set a $61.00 price target (down from $63.00) on shares of Lantheus in a research note on Monday. The Goldman Sachs Group set a $77.00 price target on Lantheus and gave the stock a “neutral” rating in a research report on Wednesday, October 8th. Mizuho cut their price objective on Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, August 7th. Finally, William Blair reissued a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $74.17.

Insider Activity

In other news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the business’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Rajiv A. Patel sold 3,365,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,812,000 shares of company stock valued at $382,427,380 in the last quarter. Company insiders own 2.00% of the company’s stock.

Lantheus Stock Performance

NASDAQ:LNTH opened at $53.37 on Wednesday. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29. The company has a fifty day simple moving average of $53.96 and a two-hundred day simple moving average of $67.56. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The company has a market cap of $3.54 billion, a price-to-earnings ratio of 14.19 and a beta of 0.04.

Lantheus (NASDAQ:LNTH) last released its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The firm had revenue of $92.51 million during the quarter. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.